Joshi J Alumkal

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. pmc Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation
    Lina Gao
    Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, United States of America
    PLoS ONE 8:e63563. 2013
  2. pmc Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers
    Joshi J Alumkal
    Oregon Health and Science University, Knight Cancer Institute, Portland, OR 97239, USA
    Cancer Discov 2:979-81. 2012
  3. pmc Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study
    Sheila Weinmann
    The Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon 97227, USA
    Prostate 73:1371-7. 2013
  4. pmc Effect of DNA methylation on identification of aggressive prostate cancer
    Joshi J Alumkal
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    Urology 72:1234-9. 2008
  5. pmc C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results
    Renee C Prins
    Division of Hematology and Medical Oncology, Oregon Health and Science University Sam Jackson Park Rd, Portland, OR 97239, USA
    Urol Oncol 30:33-7. 2012

Collaborators

Detail Information

Publications5

  1. pmc Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation
    Lina Gao
    Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, United States of America
    PLoS ONE 8:e63563. 2013
    ..Our results define a new link between two critical proteins in prostate cancer - AR and c-Myc - and demonstrate the potential of AR and c-Myc-directed therapies to improve prostate cancer control...
  2. pmc Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers
    Joshi J Alumkal
    Oregon Health and Science University, Knight Cancer Institute, Portland, OR 97239, USA
    Cancer Discov 2:979-81. 2012
    ..This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype...
  3. pmc Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study
    Sheila Weinmann
    The Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon 97227, USA
    Prostate 73:1371-7. 2013
    ....
  4. pmc Effect of DNA methylation on identification of aggressive prostate cancer
    Joshi J Alumkal
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    Urology 72:1234-9. 2008
    ..DNA methylation of promoter regions leads to gene silencing in many cancers. In this study, we assessed the effect of DNA methylation on the identification of recurrent prostate cancer...
  5. pmc C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results
    Renee C Prins
    Division of Hematology and Medical Oncology, Oregon Health and Science University Sam Jackson Park Rd, Portland, OR 97239, USA
    Urol Oncol 30:33-7. 2012
    ..CRP is a readily measurable biomarker that has the potential to improve prognostic models and should be validated in a prospective clinical trial...